An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation

Drug Metabolism and Disposition

Volumn 28, Issue 9, 2000, Pages 1031-1037

  Mayhew, Bradley S ^a   Jones And, David R ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450; DILTIAZEM; DRUG METABOLITE; FLUOXETINE; MIDAZOLAM; N DESMETHYL DILTIAZEM; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MICROSOME; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CALCIUM CHANNEL BLOCKERS; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0033831197     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting
2. Clarithromycin-carbamazepine interaction: A case report
3. The interaction of diltiazem with lovastatin and pravastatin
4. Dose of midazolam should be reduced during diltiazem and verapamil treatments
5. Inhibition of alfentanil metabolism by erythromycin
6. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs
7. Serum binding of diltiazem in humans
8. Pharmacokinetic interaction between cyclosporin and diltiazem
9. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization
10. Cytochrome P450 turnover
11. The pharmacokinetics of clarithromycin and its 14-OH metabolite
12. Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes
13. Enhanced rates of cytochrome P450 metabolic-intermediate complex formation from nonmacrolide amines in rifampicin-treated rabbit liver microsomes
14. Pharmacokinetic drug interactions with antimicrobial agents
15. Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers
16. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
17. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
18. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily
19. Characterization of dextromethorphan N-demethylation by human liver microsomes
20. Fluoxetine impairs clearance of alprazolam but not of clonazepam
21. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
22. Drug metabolite kinetics
23. Diltiazem inhibition of CYP3A activity is due to metabolite intermediate complex formation
24. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals
25. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine
26. Life threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers
27. A potentially hazardous interaction between erythromycin and midazolam
28. The carbon monoxide-binding pigment of liver microsomes
29. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes
30. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (Cyclosporin A Oxidase) in primary cultures of human hepatocytes and in liver microsomes
31. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
32. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'hydroxy midazolam formation in vitro
33. Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the Abbott Laboratories experience
34. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction
35. Kinetics of suicide substrates. Steady-state treatments and computer-aided exact solutions
36. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides
37. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem
38. Transient-phase kinetics of enzyme inactivation induced by suicide substrates
39. Kinetics of suicide substrates
40. Kinetics of suicide substrates. Practical procedures for determining parameters
41. Suicide substrates for flavoprotein enzymes
42. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture
43. A physiological approach to hepatic drug clearance